Proteomic approach reveals metastatic melanoma resistance to therapies

Source: Drug Target Review, October 2019

Using a proteomics approach, a study has identified why over half of patients with metastatic melanoma do not respond to immunotherapy treatments. The researchers say their findings could help to improve responses to therapies.

Tel Aviv University (TAU) and Sheba Medical Center, both Israel, conducted the research. The research team utilised a “protein mapping” technique.

The study compared tumour samples from a group in which immunotherapy was successful and a second in which immunotherapy was not. They discovered differences in the metabolism of the cancer cells in the two groups.

Read the original full article